Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.08 | N/A | +3.18% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.08 | N/A | +3.18% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on their pipeline and future projects. They emphasized the importance of innovation in driving growth.
Management highlighted ongoing efforts in research and development.
They expressed confidence in long-term growth despite current market challenges.
Gilead Sciences reported a stronger-than-expected EPS, indicating solid performance in that area. However, the lack of revenue data and guidance may leave investors uncertain about the company's future direction. The stock reaction is not available, but the positive EPS surprise suggests some confidence in their financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HONEYWELL INTL INC
Jul 22, 2016